Get the Stockscreener App
1.63
0.30%
-0.01
Opko Health Inc stock is traded at $1.63, with a volume of 3.30M.
It is down -0.30% in the last 24 hours and up +11.22% over the past month.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals.
See More
Previous Close:
$1.64
Open:
$1.62
24h Volume:
3.30M
Relative Volume:
0.98
Market Cap:
$1.12B
Revenue:
$863.49M
Net Income/Loss:
$-188.86M
P/E Ratio:
-6.037
EPS:
-0.27
Net Cash Flow:
$-44.47M
1W Performance:
+4.14%
1M Performance:
+11.22%
6M Performance:
+23.86%
1Y Performance:
+14.34%
1-Day Range:
$1.62
$1.68
1-Week Range:
$1.56
$1.71
52-Week Range:
$0.8516
$1.745
Opko Health Inc Stock (OPK) Company Profile
Name
Opko Health Inc
Sector
Industry
Phone
305-575-4181
Address
4400 BISCAYNE BLVD., MIAMI, FL
Compare OPK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| OPK | 1.635 | 1.12B | 863.49M | -188.86M | -44.47M | -0.27 |
| TMO | 500.61 | 192.46B | 42.37B | 6.14B | 7.78B | 15.26 |
| DHR | 229.52 | 165.90B | 23.74B | 3.89B | 4.98B | 7.93 |
| A | 126.36 | 36.48B | 6.50B | 1.41B | 1.42B | 3.82 |
| IDXX | 421.19 | 34.55B | 3.84B | 866.24M | 792.60M | 9.80 |
| IQV | 190.71 | 34.31B | 15.32B | 1.41B | 1.96B | 5.95 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-29-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Dec-15-22 | Initiated | H.C. Wainwright | Buy |
| Jan-24-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-21-21 | Initiated | Ladenburg Thalmann | Buy |
| Nov-25-19 | Initiated | Piper Jaffray | Overweight |
| Mar-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-14-17 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-21-16 | Reiterated | Standpoint Research | Buy |
| Jun-03-16 | Initiated | Standpoint Research | Buy |
| Mar-31-16 | Reiterated | Barrington Research | Outperform |
| Oct-16-15 | Initiated | JP Morgan | Overweight |
| Sep-11-15 | Downgrade | Jefferies | Buy → Hold |
| Mar-03-15 | Downgrade | Oppenheimer | Outperform → Perform |
| May-12-14 | Reiterated | Oppenheimer | Outperform |
| Mar-14-14 | Initiated | Oppenheimer | Outperform |
| Nov-13-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-30-13 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-22-12 | Initiated | Barrington Research | Outperform |
| Dec-01-11 | Reiterated | Ladenburg Thalmann | Buy |
| Jul-14-11 | Initiated | Ladenburg Thalmann | Buy |
View All
Opko Health Inc Stock (OPK) Latest News
Hyperparathyroidism Treatment Market Growth Trends, Regional - openPR
NextPlat to Showcase OPKO Healthcare Products at Major Chinese Health Expo | NXPL Stock News - StockTitan
OPKO Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Opko health CEO Phillip Frost buys $161,980 in stock - Investing.com
Rubric Capital Management LP's Strategic Acquisition in OPKO Hea - GuruFocus.com
Barrington Research Estimates OPKO Health FY2028 Earnings - MarketBeat
Insider Buying: OPKO Health Chairman & CEO Bought US$422k Of Shares - Simply Wall St
Phillip Frost Buys Handful Of Shares In OPKO Health - Yahoo Finance
OPKO Health: Q3 Earnings Snapshot - AOL
OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Purchases 280,183 Shares - MarketBeat
OPKO Health's (OPK) Outperform Rating Reiterated at Barrington Research - MarketBeat
OPKO Health, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Simply Wall St
OPKO Health, Inc. (NASDAQ:OPK) Q3 2024 Earnings Call Transcript - Insider Monkey
OPKO Health Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance UK
Opko health CEO Phillip Frost purchases $421,535 in stock By Investing.com - Investing.com Nigeria
Opko health CEO Phillip Frost purchases $421,535 in stock - Investing.com India
Earnings call: OPKO Health Q3 2024 results show promise amid challenges - Investing.com
Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates - StockTitan
OPK Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts - Yahoo Finance
OPKO Health Shows Strategic Progress in Q3 2024 - TipRanks
Opko Health (OPK) Q3 2024 Earnings Call Transcript - AOL
Here's What Key Metrics Tell Us About OPKO Health (OPK) Q3 Earnings - Yahoo Finance
Opko Health earnings beat by $0.12, revenue fell short of estimates - Investing.com Canada
OPKO Health (OPK) Q3 Earnings Surpass Estimates - Yahoo Finance
OPKO Health Reports Third Quarter 2024 Business Highlights and Financial Results - The Manila Times
Aspira Women's Health Expands Co-Marketing and Distribution Collaboration with BioReference® to Include OvaWatch® - The Manila Times
Aspira Women’s Health Expands Co-Marketing and Distribution Collaboration with BioReference® to Include OvaWatch® - Yahoo Finance
Health Check-up Market is Expected to Soar in the Upcoming Years - openPR
OPKO Health, Inc. (NASDAQ:OPK) Shares Bought by Assenagon Asset Management S.A. - MarketBeat
OPKO Health (OPK) Set to Announce Earnings on Thursday - MarketBeat
Head to Head Review: OPKO Health (NASDAQ:OPK) vs. OptiNose (NASDAQ:OPTN) - Defense World
OPKO Health, Inc.'s (NASDAQ:OPK) CEO Phillip Frost is the most upbeat insider, and their holdings increased by 9.6% last week - Simply Wall St
Here's Why You Should Retain OPKO Health Stock in Your Portfolio - MSN
OPKO Health to Report Third Quarter 2024 Financial Results on November 7, 2024 - The Manila Times
Opko Health Inc (OPK-Q) QuotePress Release - The Globe and Mail
OPKO Health (NASDAQ:OPK) Trading 4.7% HigherShould You Buy? - MarketBeat
SECONDARY HYPERPARATHYROIDISM MARKET TO WITNESS UPSURGE - openPR
Us Prostate Cancer Instruments And Test Market Report: - openPR
With 50% ownership, OPKO Health, Inc. (NASDAQ:OPK) insiders have a lot riding on the company's future - Yahoo Finance
Hypopituitarism Market Forecasted to Surge in Coming Years, - openPR
GeneDx (NASDAQ:WGS) Reaches New 52-Week HighTime to Buy? - MarketBeat
35,157 Shares in OPKO Health, Inc. (NASDAQ:OPK) Bought by Algert Global LLC - Defense World
Renaissance Technologies LLC Cuts Stock Holdings in OPKO Health, Inc. (NASDAQ:OPK) - Defense World
OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies - MSN
OPKO Health (NASDAQ:OPK) Stock Price Up 4.1%Time to Buy? - MarketBeat
Squarepoint Ops LLC Invests $592,000 in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
Opko Health Inc Stock (OPK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Opko Health Inc Stock (OPK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 08 '24 |
Buy |
1.50 |
280,183 |
421,535 |
211,512,405 |
2.78%
1.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):